News | Stents Drug Eluting

The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

Home September 30, 2019
Home
News | Stents Drug Eluting

A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

Home September 30, 2019
Home
Videos | Structural Heart

A discussion with William O’Neill, M.D., director of the Henry Ford structural heart program, Ruth Fisher, MBA, vice ...

Home September 30, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.

Home September 30, 2019
Home
Videos | Cardiovascular Business

A discussion with Ruth Fisher, MBA, vice president of the Henry Ford Hospital structural heart program, and Janet Wyman ...

Home September 30, 2019
Home
Videos | Cath Lab

A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS. They explain ...

Home September 28, 2019
Home
Videos | Chronic Total Occlusion (CTO)

A discussion with Khaldoon Alaswad, M.D., director, cardiac catheterization lab, Henry Ford Hospital, on treating ...

Home September 28, 2019
Home
News | Heart Failure

Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study. CorCinch FMR evaluated the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of systolic heart failure. The data was presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Sept. 24-29 in San Francisco.

Home September 27, 2019
Home
Technology | Ventricular Assist Devices (VAD)

Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days.

Home September 27, 2019
Home
News | Virtual and Augmented Reality

EchoPixel introduced what it calls the first-ever intraoperative software to provide naked-eye, touchless interactive 3-D anatomical imaging to support structural heart procedures in the cath lab, operating room (OR) and hybrid OR. The introduction was made at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 meeting, September 25-29, in San Francisco. The company will showcase the turnkey intraoperative solution, which is pending U.S. Food and Drug Administration (FDA) 510(k) clearance, as part of its existing integrated suite of mixed reality software solutions that assist cardiologists and surgeons with visualization of live 3-D medical images during a procedure for more precise catheter and device placement and personalized planning.

Home September 27, 2019
Home
Videos

Akshay Khandelwal, M.D., director of medical operations at the Henry Ford Heart and Vascular Institute, Detroit, and ...

Home September 27, 2019
Home
Videos

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC type 2, 3 or 5 bleeding in high-bleed-risk patients who underwent percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT) at 12 months. Brilinta monotherapy (90 mg twice daily) was compared to Brilinta plus low-dose aspirin.

Home September 26, 2019
Home
Technology | Computed Tomography (CT)

The U.S. Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT, an intelligent software assistant from Siemens Healthineers that brings artificial intelligence (AI) to computed tomography (CT). They include the AI-Rad Companion Engine (K183272), Pulmonary (K183271) and Cardiovascular (K183268) modules. Representing the first intelligent assistant of the new AI-Rad Companion platform, AI-Rad Companion Chest CT helps radiologists interpret images of the thorax (chest) quickly with desired accuracy and precision, and automatically documents these findings as structured reports.

Home September 26, 2019
Home
News | Magnetic Resonance Imaging (MRI)

Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to experts when using automated machine learning, according to new research. The study was published in Circulation: Cardiovascular Imaging, an American Heart Association journal.

Home September 25, 2019
Home
Subscribe Now